Evaluation of Neovis® Total Multi Versus Systane® Balance on Ocular Dryness Associated With Meibomian Gland Dysfunction
Multicentric, Randomized, Comparative Clinical Study on the Evaluation of the Efficacy and Safety of Neovis® Total Multi Versus Systane® Balance on the Treatment of Ocular Dryness Associated With Meibomian Gland Dysfunction
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Verwacht)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Laure Chauchat
- Telefoonnummer: +33 (0)4 89 08 90 98
- E-mail: laure.chauchat@horus-pharma.com
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Presenting dry eye symptoms for at least 6 months.
- OSDI (Ocular Surface Disease Index) ≥ 18
At least one eye eligible with:
- sum of peripheral corneal and conjunctival staining ≥ 4 and ≤ 9 (Oxford 0-15 grading scheme) AND
- sum of 3 measurements of Tear film Break-Up Time (TBUT) ≤ 15s
- Meibomian Gland Dysfunction on at least one eye (same eye eligible) with a score of 1 or higher for meibum quality score (from 0: clear to 3: toothpaste/obstruction) and evidence of partial or whole missing Meibomian Glands.
- Ability and willingness to apply eyelid hygiene during the whole study, including wash-out period.
- Having given freely and expressly his/her informed consent.
- Able to comply with the study requirements, as defined in the present CIP, at the Investigator's appreciation.
- In France: subject being affiliated to a health social security system.
- Female subjects of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end.
Exclusion Criteria:
- Pregnant or nursing woman or planning a pregnancy during the study.
- Subject deprived of freedom by administrative or legal decision.
- Subject in a social or health institution
- Subject who is under guardianship or who is not able to express his/her consent.
- Use of contact lenses in either eye during the study.
- Far best-corrected visual acuity ≤ 1/10.
Subject with severe ocular dryness with one of these conditions:
- Eyelid or blinking malfunction
- Corneal disorders not related to dry eye syndrome
- Ocular metaplasia
- Filamentous keratitis
- Corneal neovascularization
- History of ocular traumatism, ocular infection or ocular inflammation within the last 3 months.
- History of ocular allergy or ocular herpes within the last 12 months.
- Subjects who underwent ocular surgery, including laser surgery, in either eye within the last 6 months.
- Any troubles of the ocular surface not related to dry eye syndrome.
- Use of the following ocular treatments: isotretinoïd, cyclosporine, tacrolimus, sirolimus, pimecrolimus during the month preceding the inclusion.
- IOP > 21 mmHg
- Uncontrolled systemic disease
- Alcohol abuse
- Psychiatric disorders
- Cognitive impairment that could affect evaluation of preferences or inability to understand written patient information
- Participation in other clinical studies in the last month
- Hypersensitivity to one or more components of the study product
- Dry eye due to systemic disease, concomitant medication, malign conditions or idiopathic causes
- Punctual plugs during the past 3 months
- Use of lipid-containing eye drops during the past 3 months
- Use of other therapeutic ophthalmics during the past 3 months
- Earlier participation at this clinical trial or the patient being an investigator or a member of the personnel involved at this clinical trial
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Onderzoeksproduct
|
1 drop in each eye, 4 times per day
|
|
Actieve vergelijker: Comparator
|
1 drop in each eye, 4 times per day
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Tear-Film Break Up Time (TBUT)
Tijdsspanne: 28 days
|
Evaluation of the non-inferiority of Neovis® Total Multi in comparison with Systane® Balance, in terms of TBUT improvement, on worse eye
|
28 days
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Tear-Film Break Up Time (TBUT) (optreden)
Tijdsspanne: 84 dagen
|
Belangrijkste verandering ten opzichte van de uitgangswaarde van de Tear-Film Break Up Time (TBUT) in het slechtste oog en het contralaterale oog
|
84 dagen
|
|
Cornea and conjunctiva staining (Oxford score) (performance)
Tijdsspanne: 28 days
|
Main change from baseline of cornea and conjunctiva staining (Oxford score) in the worse eye and contralateral eye
|
28 days
|
|
Kleuring van hoornvlies en bindvlies (Oxford-score) (prestatie)
Tijdsspanne: 84 dagen
|
Belangrijkste verandering ten opzichte van de basislijn van kleuring van het hoornvlies en het bindvlies (Oxford-score) in het slechtste oog en het contralaterale oog
|
84 dagen
|
|
Meibomian gland expression (performance)
Tijdsspanne: 28 days
|
Main change from baseline of meibomian gland expression score in the worse eye and contralateral eye
|
28 days
|
|
Meibomian gland expression (performance)
Tijdsspanne: 84 days
|
Main change from baseline of meibomian gland expression score in the worse eye and contralateral eye
|
84 days
|
|
Meibum quality (performance)
Tijdsspanne: 28 days
|
Main change from baseline of meibum quality score in the worse eye and contralateral eye
|
28 days
|
|
Meibum quality (performance)
Tijdsspanne: 84 days
|
Main change from baseline of meibum quality score in the worse eye and contralateral eye
|
84 days
|
|
Meiboscopy (performance)
Tijdsspanne: 28 days
|
Main change from baseline of the number of partially missing or dropout meibomian glands in the worse eye and contralateral eye
|
28 days
|
|
Meiboscopy (performance)
Tijdsspanne: 84 days
|
Main change from baseline of the number of partially missing or dropout meibomian glands in the worse eye and contralateral eye
|
84 days
|
|
Eyelid margin abnormalities (performance)
Tijdsspanne: 28 days
|
Main change from baseline of the eyelid margin abnormalities score in the worse eye and contralateral eye
|
28 days
|
|
Eyelid margin abnormalities (performance)
Tijdsspanne: 84 days
|
Main change from baseline of the eyelid margin abnormalities score in the worse eye and contralateral eye
|
84 days
|
|
OSDI (questionnaire) (performance)
Tijdsspanne: 28 days
|
Main change from baseline of OSDI (Ocular Surface Disease Index) in the worse eye and contralateral eye
|
28 days
|
|
OSDI (questionnaire) (performance)
Tijdsspanne: 84 days
|
Main change from baseline of OSDI (Ocular Surface Disease Index) in the worse eye and contralateral eye
|
84 days
|
|
Global performance by the investigator (performance)
Tijdsspanne: 28 days
|
Global performance assessment by the investigator using a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)
|
28 days
|
|
Globale prestatie van de onderzoeker (prestatie)
Tijdsspanne: 84 dagen
|
Globale prestatiebeoordeling door de onderzoeker met behulp van een vierpuntsschaal (onvoldoende, niet erg bevredigend, bevredigend, zeer bevredigend)
|
84 dagen
|
|
Global performance by the patient (performance)
Tijdsspanne: 28 days
|
Global performance assessment by the patient using a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)
|
28 days
|
|
Global performance by the patient (performance)
Tijdsspanne: 84 days
|
Global performance assessment by the patient using a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)
|
84 days
|
|
Global tolerance by the investigator (safety)
Tijdsspanne: 28 days
|
Global tolerance assessment by the investigator using a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)
|
28 days
|
|
Global tolerance by the investigator (safety)
Tijdsspanne: 84 days
|
Global tolerance assessment by the investigator using a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)
|
84 days
|
|
Global tolerance by the patient (safety)
Tijdsspanne: 28 days
|
Global tolerance assessment by the patient using a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)
|
28 days
|
|
Global tolerance by the patient (safety)
Tijdsspanne: 84 days
|
Global tolerance assessment by the patient using a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)
|
84 days
|
|
Intensity of ocular symptoms upon instillation (safety)
Tijdsspanne: 28 days
|
Evaluation of intensity of ocular symptoms upon instillation on a scale from 0 (none) to 3 (severe)
|
28 days
|
|
Intensity of ocular symptoms upon instillation (safety)
Tijdsspanne: 84 days
|
Evaluation of intensity of ocular symptoms upon instillation on a scale from 0 (none) to 3 (severe)
|
84 days
|
|
Duration of ocular symptoms upon instillation (safety)
Tijdsspanne: 28 days
|
Evaluation of duration of ocular symptoms upon instillation in seconds/minutes/hours
|
28 days
|
|
Duration of ocular symptoms upon instillation (safety)
Tijdsspanne: 84 days
|
Evaluation of duration of ocular symptoms upon instillation in seconds/minutes/hours
|
84 days
|
|
Frequency of ocular symptoms upon instillation (safety)
Tijdsspanne: 28 days
|
Evaluation of frequency of ocular symptoms upon instillation on a scale from 1 (rarely) to 4 (very often)
|
28 days
|
|
Frequency of ocular symptoms upon instillation (safety)
Tijdsspanne: 84 days
|
Evaluation of frequency of ocular symptoms upon instillation on a scale from 1 (rarely) to 4 (very often)
|
84 days
|
|
Number of Adverse Events
Tijdsspanne: 84 days
|
Collection of ocular and systemic adverse events
|
84 days
|
Andere uitkomstmaten
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Non-Invasive Tear film Break-Up Time (NIBUT) (exploratory, optional)
Tijdsspanne: 28 days
|
Main change from baseline of Non-Invasive Tear film Break-Up Time (NIBUT) in the worse eye and contralateral eye
|
28 days
|
|
Non-Invasive Tear film Break-Up Time (NIBUT) (exploratory, optional)
Tijdsspanne: 84 days
|
Main change from baseline of Non-Invasive Tear film Break-Up Time (NIBUT) in the worse eye and contralateral eye
|
84 days
|
|
Lipid layer thickness (exploratory, optional)
Tijdsspanne: 28 days
|
Main change from baseline of lipid layer thickness with interferometry methods in the worse eye and contralateral eye
|
28 days
|
|
Lipid layer thickness (exploratory, optional)
Tijdsspanne: 84 days
|
Main change from baseline of lipid layer thickness with interferometry methods in the worse eye and contralateral eye
|
84 days
|
|
Functional visual acuity (exploratory, optional)
Tijdsspanne: 28 days
|
Main change from baseline of functional visual acuity in the worse eye and contralateral eye
|
28 days
|
|
Functional visual acuity (exploratory, optional)
Tijdsspanne: 84 days
|
Main change from baseline of functional visual acuity in the worse eye and contralateral eye
|
84 days
|
|
Super Oxyde Dismutase (SOD) dosage (exploratory, optional)
Tijdsspanne: 84 days
|
Main change from baseline of SOD1 and SOD2 in the worse eye
|
84 days
|
|
Goblet cells analysis (exploratory, optional)
Tijdsspanne: 84 days
|
Main change from baseline of Goblet cells in the worse eye
|
84 days
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Hoffart Louis, Vision Sud
Studie record data
Bestudeer belangrijke data
Studie start (Verwacht)
Studie start
Primaire voltooiing (Verwacht)
Primaire voltooiing
Studie voltooiing (Verwacht)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- 21E1007
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .